# SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

> **NCT01086254** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 119 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Iniparib
- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT01086254
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2013-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01086254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01086254, "SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01086254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*